Literature DB >> 10589081

Splenic involvement by blastic mantle cell lymphoma (large cell/anaplastic variant) mimicking splenic marginal zone lymphoma.

M Mollejo1, E Lloret, J Solares, J M Bergua, M Mateo, M A Piris.   

Abstract

The most cases of splenic marginal zone lymphoma (SMZL) seem to respond favorably to splenectomy. The diagnosis of this lymphoma is mainly based on the recognition of a micronodular pattern of splenic involvement with marginal zone differentiation. However, it is possible to find so-called "marginal zone differentiation" in splenic involvement by other small B-cell lymphomas, particularly mantle cell lymphoma (MCL) and follicular lymphoma. We report a case of blastic MCL, large cell/anaplastic variant with a high level of clinical aggressiveness, showing biphasic cytology and a micronodular pattern which resembles SMZL. A single biopsy corresponding to this case shows two phases of tumoral progression in a MCL, a rare finding in MCL. In conclusion, the differential diagnosis of SMZL must take the possibility of a blastic MCL with biphasic cytology into account, as the case here. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589081     DOI: 10.1002/(sici)1096-8652(199912)62:4<242::aid-ajh8>3.0.co;2-a

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

Review 1.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Blastoid variant of mantle cell lymphoma with lactic acidosis: a case report.

Authors:  Korenori Ohtsubo; Rie Imamura; Ritsuko Seki; Koichi Ohshima; Michitoshi Hashiguchi; Kazuaki Yakushiji; Koji Yoshimoto; Hideaki Ogata; Takashi Okamura; Michio Sata
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

3.  Mantle cell lymphoma with features of marginal-zone lymphoma.

Authors:  Ulla Randen; Olav Erich Yri; Anne Tierens; Sverre Heim; Klaus Beiske; Jan Delabie
Journal:  J Hematop       Date:  2011-03-02       Impact factor: 0.196

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.